Generated by Rank Math SEO, this is an llms.txt file designed to help LLMs better understand and index this website.

# Dr Raman Narang: Medical & Precision Oncologist

## Sitemaps
[XML Sitemap](https://drramannarang.com/sitemap_index.xml): Includes all crawlable and indexable pages.

## Posts
- [What Is Precision Oncology and How Does It Help in Cancer Treatment?](https://drramannarang.com/precision-oncology-cancer-treatment/): Direct answer: Precision oncology is an approach to cancer treatment where the oncologist studies the cancer’s biology, biomarkers, molecular profile and the patient’s clinical condition before choosing treatment. In simple terms, it helps move beyond a “one-size-fits-all” cancer plan and supports more informed decisions about chemotherapy, targeted therapy, immunotherapy, clinical trials, genetic counselling and follow-up. Precision oncology cancer treatment is most useful when test results can meaningfully change treatment choice, sequencing or family-risk assessment.
- [What Is Liquid Biopsy? How a Simple Blood Test Is Changing Cancer Diagnosis](https://drramannarang.com/liquid-biopsy-ctdna-cancer-blood-test/): Direct Answer: A liquid biopsy is a blood-based cancer test that looks for tumor-derived material, especially circulating tumor DNA or ctDNA, released by cancer cells into the bloodstream. It can help identify actionable mutations, monitor treatment response, and detect resistance when tissue biopsy is difficult or insufficient. It is not a universal replacement for tissue biopsy, but it is becoming an important part of precision oncology decision-making. :contentReference{index=1}
- [Gynecological Oncology: Why Women’s Cancer Care Needs a More Focused, Personalized Approach](https://drramannarang.com/gynecological-oncology-why-womens-cancer-care-needs-a-more-focused-personalized-approach/): Gynecological oncology deals with cancers of the female reproductive system, including cervical cancer, ovarian cancer, endometrial/uterine cancer, vulvar cancer, vaginal cancer, and fallopian tube cancer. These cancers are important because many warning signs are ignored, screening is underused, and treatment often needs a highly personalized approach based on stage, age, fertility goals, tumor biology, genetics, and molecular testing. Women's cancer is a crucial area that requires attention. (CDC)
- [Targeted Therapy and Chemotherapy: Understanding the Difference](https://drramannarang.com/targeted-therapy-and-chemotherapy-understanding-the-difference/): Direct Answer:Targeted Therapy and Chemotherapy are two fundamental approaches used in cancer treatment, but they work in very different ways. Chemotherapy affects rapidly dividing cells broadly, while targeted therapy focuses on specific molecular abnormalities within cancer cells. Understanding this distinction is central to modern precision oncology, where treatment decisions are increasingly guided by tumor biology rather than only cancer stage.
- [Fertility After Cancer Treatment: What Survivors Need to Know](https://drramannarang.com/fertility-after-cancer-treatment/): Many cancer survivors retain the possibility of having children after treatment, although fertility outcomes depend on factors such as age, treatment type, and baseline reproductive health. Chemotherapy, radiation therapy, and certain surgeries may affect reproductive capacity, but recovery of fertility can occur months to years after treatment in some individuals.Modern oncology care increasingly integrates fertility counseling, reproductive monitoring, and assisted reproductive technologies to support survivorship and long-term quality of life.
- [Fertility Preservation Before Cancer Treatment](https://drramannarang.com/fertility-preservation-before-cancer-treatment/): Certain cancer treatments such as chemotherapy, radiotherapy, and pelvic surgery can impair fertility by damaging reproductive cells or hormonal pathways. Fertility preservation allows patients to safeguard future reproductive potential before initiating cancer therapy. Techniques such as sperm banking, egg freezing, embryo cryopreservation, and ovarian tissue preservation are now standard components of modern oncologic care for eligible patients.Discussing fertility early in the treatment planning phase helps ensure that cancer therapy proceeds without compromising long-term quality of life for younger patients.
- [When to Seek Second Opinion In Cancer ?](https://drramannarang.com/when-to-seek-second-opinion-in-cancer/): A second opinion in cancer care is most valuable when a patient is newly diagnosed, when treatment decisions involve major interventions such as chemotherapy or surgery, or when multiple treatment pathways are possible. A structured review of pathology reports, imaging studies, and molecular biomarkers can sometimes refine staging or identify additional therapeutic options. In modern oncology, second opinions are increasingly used to evaluate precision oncology approaches, including targeted therapy and immunotherapy.
- [When Immunotherapy Works Even With Low PD-L1 Expression](https://drramannarang.com/when-immunotherapy-works-even-with-low-pd-l1-expression/): While PD-L1 testing is widely used to guide immunotherapy decisions, a low or negative PD-L1 result does not necessarily mean immunotherapy will not work. Clinical studies have shown that some patients with low PD-L1 expression still benefit from immune checkpoint inhibitors, particularly when immunotherapy is combined with chemotherapy or used in specific clinical settings. This reflects the complexity of tumor-immune interactions and highlights the broader role of precision oncology beyond a single biomarker.
- [The Role of PD-L1 Testing Before Starting Immunotherapy](https://drramannarang.com/role-of-pd-l1-testing-before-immunotherapy/): PD-L1 testing is an important biomarker assessment used to guide the use of immunotherapy in several cancers, particularly lung cancer and other solid tumors. By measuring PD-L1 expression on tumor cells or immune cells, clinicians can estimate the likelihood that a patient will respond to immune checkpoint inhibitors. While PD-L1 levels do not perfectly predict response, the test helps stratify patients and refine treatment strategy within the broader framework of precision oncology.
- [Molecular Subtypes of Breast Cancer and Their Treatment Implications](https://drramannarang.com/molecular-subtypes-of-breast-cancer-and-their-treatment-implications/): Molecular subtypes of Breast cancer is biologically classified using ER, PR, and HER2 status (and sometimes proliferation/genomic assays). These markers define clinically meaningful subtypes—HR-positive, HER2-positive, and triple-negative—which directly determine the backbone of treatment (endocrine therapy, anti-HER2 therapy, chemotherapy, and selected immunotherapy).
- [When Should Patients Undergo Genetic Testing for Cancer Risk?](https://drramannarang.com/when-should-patients-undergo-genetic-testing-for-cancer-risk/): Genetic testing for cancer risk should be considered when personal or family history suggests a hereditary cancer syndrome. This includes early-onset cancers, multiple affected relatives, rare tumor types, or known pathogenic mutations in the family. Testing helps identify inherited mutations that may influence screening strategies, preventive decisions, and treatment planning.
- [What Is Biomarker-Driven Therapy in Modern Oncology?](https://drramannarang.com/what-is-biomarker-driven-therapy-in-modern-oncology/): Biomarker-driven therapy is a precision oncology approach where cancer treatment is selected based on specific molecular characteristics of a tumor rather than its location alone. These biomarkers may include gene mutations, protein expression levels, or genomic signatures. By identifying actionable targets, therapy becomes more individualized, potentially improving outcomes and minimizing unnecessary toxicity. Additionally, research continues to demonstrate the efficacy of this approach across various cancer types, emphasizing the importance of continuous advancements in molecular diagnostics and treatment modalities.
- [Individualizing Cancer Treatment in the Elderly and Young Adults](https://drramannarang.com/individualizing-cancer-treatment-in-the-elderly-and-young-adults/): Cancer treatment should not be determined by age alone. Elderly patients require physiologic assessment beyond chronological age, while adolescents and young adults (AYA) require biologically precise and survivorship-focused strategies. Individualization is achieved through structured evaluation of fitness, tumor biology, long-term risk, and life-stage priorities. Modern oncology integrates geriatric assessment and precision medicine to avoid both undertreatment and overtreatment. This approach is essential for individualizing-cancer-treatment-in-the-elderly-and-young-adults.
- [Molecular Subtypes Across Common Cancers: Why Biology Matters More Than Stage](https://drramannarang.com/molecular-subtypes-in-cancer/): Cancer stage describes where the disease has spread. Molecular subtypes in cancer explains how the cancer behaves. In modern oncology, treatment decisions increasingly depend on tumor biology rather than anatomy alone. Two patients with the same stage may require entirely different therapies based on genetic drivers and biomarker expression.
- [How Structured Second Opinions Improve Cancer Treatment Decisions](https://drramannarang.com/how-structured-second-opinions-in-cancer/): A structured second opinion in oncology is a systematic re-evaluation of diagnosis, staging, pathology, molecular data, and treatment sequencing. It does not replace the primary oncologist but strengthens decision clarity. In complex cancers, even small refinements in staging or biomarker interpretation can significantly influence outcomes and long-term toxicity.
- [When and Why Genetic Testing Matters in Cancer Treatment and Prevention](https://drramannarang.com/genetic-testing-in-cancer-treatment-prevention/): Genetic testing in cancer evaluates inherited (germline) mutations that may influence both treatment decisions and long-term risk assessment. It helps identify individuals at increased lifetime cancer risk and guides preventive strategies, screening intensity, and in some cases, targeted therapy selection. Not every patient requires genetic testing, but when appropriately indicated, it significantly alters clinical management for both patients and families.
- [The Foundations of Precision Oncology in Modern Cancer Care](https://drramannarang.com/the-foundations-of-precision-oncology-in-modern-cancer-care/): Precision oncology is a structured approach to cancer treatment that integrates tumor biology, molecular profiling, and patient-specific clinical factors to guide therapy selection. Rather than relying solely on tumor location, modern oncology increasingly uses genomic, proteomic, and biomarker data to match patients with targeted therapies or immunotherapy. This improves treatment relevance, reduces unnecessary toxicity, and enables more rational sequencing of care.
- [How Molecular Profiling Influences Treatment Decisions in Lung Cancer](https://drramannarang.com/molecular-profiling-in-lung-cancer/): Molecular profiling in lung cancer identifies specific genetic alterations within a tumor that determine which therapy is most biologically appropriate. Instead of selecting treatment based only on stage or histology, oncologists now use biomarkers such as EGFR, ALK, ROS1, KRAS, MET, RET, and PD-L1 expression to guide targeted therapy or immunotherapy decisions. This precision-based approach improves response rates and avoids ineffective treatment strategies.

## Pages
- [Contact](https://drramannarang.com/contact/): Dr Raman Narang is a highly respected Consultant Medical Oncologist based in New Delhi, renowned for his expertise in precision oncology, cancer genetics, and molecularly guided systemic therapies. His commitment to advancing cancer treatment through personalized care is evident in his practice, where he utilizes the latest advancements in medical technology and research to provide optimal patient outcomes. Dr. Narang collaborates with a multidisciplinary team to tailor treatment plans that consider the unique genetic makeup of each patient's cancer, ensuring a comprehensive approach to oncology care.
- [Blog](https://drramannarang.com/blog/): Dr Raman Narang shares structured insights in medical oncology, precision oncology, cancer genetics, and evidence-based systemic therapies. These articles aim to simplify complex oncologic concepts while maintaining scientific accuracy and clinical relevance.
- [Media](https://drramannarang.com/media/): Dr Raman Narang Media Coverage reflects his focus on scientific clarity, patient education, and responsible public health communication.
- [International](https://drramannarang.com/international-patients/): International cancer consultation in India allows overseas patients to access structured, evidence-based oncology expertise with treatment strategy either via second opinions or virtual consultations or face to face consultation. Many prefer the International Cancer Consultation India for its tailored services.
- [Second Opinion](https://drramannarang.com/second-opinion-cancer/): A second opinion in cancer care allows patients to confirm their diagnosis, understand disease staging, and evaluate treatment options before initiating therapy. A structured review can significantly influence treatment strategy and long-term outcomes.
- [Precision Oncology](https://drramannarang.com/precision-oncology/): Precision oncology is a structured, evidence-based approach to cancer treatment that integrates tumor biology, molecular profiling, and patient-specific clinical factors.
- [About](https://drramannarang.com/about/): Dr Raman Narang is a Consultant Medical Oncologist based in New Delhi with a focused clinical practice in precision oncology, cancer genetics, immunotherapy, and molecularly guided systemic therapies. His approach integrates evidence-based international guidelines with individualized treatment planning tailored to tumour biology, genomic profiling, and patient-specific factors.
- [Home](https://drramannarang.com/): Clearer Decisions. More Personalised Cancer Care.Evidence-based medical oncology, precision oncology and structured second opinions for patients and families navigating complex cancer decisions.

## Categories
- [Cancer Genetics & Hereditary Risk](https://drramannarang.com/category/cancer-genetics/)
- [Disease-Specific Deep Dives](https://drramannarang.com/category/cancer-types/)
- [Geriatric & AYA Oncology](https://drramannarang.com/category/geriatric-aya-oncology/)
- [Gynecological Oncology](https://drramannarang.com/category/precision-oncology-cancer/gynecological-oncology/)
- [Precision Oncology](https://drramannarang.com/category/precision-oncology-cancer/)
- [Treatment Strategy & Second Opinions](https://drramannarang.com/category/treatment-options/)

## Tags

Site Owner: Dr Raman Narang
Specialty: Medical Oncology, Hematology, Precision Oncology
Location: Delhi, India

This website provides evidence-based content on precision oncology, cancer genetics, structured second opinions, and disease-specific treatment strategy. Content is written and reviewed by Dr Raman Narang, Consultant Medical Oncologist.

Core Topics:
- Precision Oncology & Molecular Medicine
- Cancer Genetics & Hereditary Risk
- Treatment Strategy & Second Opinions
- Disease-Specific Deep Dives
- Geriatric & AYA Oncology

Primary Audience:
Patients seeking expert cancer treatment guidance, second opinions, and biologically personalized cancer therapy planning.